Hostname: page-component-84b7d79bbc-tsvsl Total loading time: 0 Render date: 2024-07-28T14:22:01.270Z Has data issue: false hasContentIssue false
  • English
  • Français

Metabolic outcomes of Red yeast rice administration in patients treated with second-generation antipsychotics

Published online by Cambridge University Press:  23 March 2020

G.M. Troili ,
A. Bruno ,
G. Pandolfo ,
M. Crucitti ,
R.A. Zoccali  and
M.R.A. Muscatello
A. Bruno
Affiliation:
University of Messina, Psychiatric Unit, Department of Biomedical and Dental Sciences and Morphofunctional Imaging, Messina, Italy
G. Pandolfo
Affiliation:
University of Messina, Psychiatric Unit, Department of Biomedical and Dental Sciences and Morphofunctional Imaging, Messina, Italy
M. Crucitti
Affiliation:
University of Messina, Psychiatric Unit, Department of Biomedical and Dental Sciences and Morphofunctional Imaging, Messina, Italy
R.A. Zoccali
Affiliation:
University of Messina, Psychiatric Unit, Department of Biomedical and Dental Sciences and Morphofunctional Imaging, Messina, Italy
M.R.A. Muscatello
Affiliation:
University of Messina, Psychiatric Unit, Department of Biomedical and Dental Sciences and Morphofunctional Imaging, Messina, Italy

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Rationale

Second-generation antipsychotics (SGAs) are notoriously associated with a wide range of metabolic adverse effects, and their chronic use is related with an increased risk for the development of metabolic syndrome (MS). The nutraceutical approach to the management of MS might be a promising strategy in the prevention of cardio-metabolic risk. In this context, Red yeast rice (RYR) have been shown to have a lipid lowering effect in an increasing number of clinical studies.

Objectives

The present study was aimed to explore the efficacy and safety of RYR treatment on metabolic parameters in a sample of subjects receiving atypical antipsychotics.

Methods

Ten outpatients treated with atypical APs assumed RYR at single daily dose of 200 mg/day for 30 days. Total cholesterol, high-density lipoprotein cholesterol (HDL), low-density lipoprotein cholesterol (LDL), triglycerides, fasting levels of glucose, and glycated hemoglobin were determined.

Results

RYR administration non-resulted in a statistically significant reduction of metabolic parameters in the study sample. However, a trend for total cholesterol (T0 vs. T1: 159.6 vs. 145.6) and LDL (T0 vs. T1: 94.1 vs. 77.6) decrease was observed.

Conclusions

Our findings in patients receiving atypical antipsychotics did not confirm the beneficial effect of RYS on lipemic profiles previously found in subjects who do not take this class of drugs. Further clinical trials with adequately-powered and well-designed methodology are needed to better explore the RYS effectiveness on the SGAs-induced metabolic side effects.

Disclosure of interest

The authors have not supplied their declaration of competing interest.

Type
e-Poster Walk: Psychopharmacology and pharmacoeconomics and psychoneuroimmunology
Information
European Psychiatry , Volume 41 , Issue S1: Abstract of the 25th European Congress of Psychiatry , April 2017 , pp. S372
Copyright
Copyright © European Psychiatric Association 2017
Submit a response

Comments

No Comments have been published for this article.